KYNTRA BIO INC (KYNB) Fundamental Analysis & Valuation

NASDAQ:KYNB • US31572Q8814

Current stock price

6.78 USD
+0.32 (+4.95%)
Last:

This KYNB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. KYNB Profitability Analysis

1.1 Basic Checks

  • KYNB had negative earnings in the past year.
  • In the past year KYNB has reported a negative cash flow from operations.
  • In the past 5 years KYNB reported 4 times negative net income.
  • In the past 5 years KYNB always reported negative operating cash flow.
KYNB Yearly Net Income VS EBIT VS OCF VS FCFKYNB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M -200M -300M

1.2 Ratios

  • The Return On Assets of KYNB (153.40%) is better than 99.81% of its industry peers.
Industry RankSector Rank
ROA 153.4%
ROE N/A
ROIC N/A
ROA(3y)21.37%
ROA(5y)-4.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KYNB Yearly ROA, ROE, ROICKYNB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K

1.3 Margins

  • KYNB has a Profit Margin of 2848.63%. This is amongst the best in the industry. KYNB outperforms 100.00% of its industry peers.
  • With an excellent Gross Margin value of 91.35%, KYNB belongs to the best of the industry, outperforming 92.84% of the companies in the same industry.
  • KYNB's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 2848.63%
GM 91.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.18%
GM growth 5Y-0.78%
KYNB Yearly Profit, Operating, Gross MarginsKYNB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1K 2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. KYNB Health Analysis

2.1 Basic Checks

  • KYNB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • KYNB has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for KYNB has been increased compared to 5 years ago.
  • KYNB has a better debt/assets ratio than last year.
KYNB Yearly Shares OutstandingKYNB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M
KYNB Yearly Total Debt VS Total AssetsKYNB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • KYNB has an Altman-Z score of -20.36. This is a bad value and indicates that KYNB is not financially healthy and even has some risk of bankruptcy.
  • KYNB's Altman-Z score of -20.36 is on the low side compared to the rest of the industry. KYNB is outperformed by 83.75% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -20.36
ROIC/WACCN/A
WACC12.83%
KYNB Yearly LT Debt VS Equity VS FCFKYNB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 3.39 indicates that KYNB has no problem at all paying its short term obligations.
  • KYNB has a Current ratio of 3.39. This is comparable to the rest of the industry: KYNB outperforms 41.78% of its industry peers.
  • A Quick Ratio of 3.26 indicates that KYNB has no problem at all paying its short term obligations.
  • With a Quick ratio value of 3.26, KYNB perfoms like the industry average, outperforming 41.39% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.39
Quick Ratio 3.26
KYNB Yearly Current Assets VS Current LiabilitesKYNB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. KYNB Growth Analysis

3.1 Past

  • KYNB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.58%, which is quite impressive.
  • KYNB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -95.87%.
  • Measured over the past years, KYNB shows a very negative growth in Revenue. The Revenue has been decreasing by -48.41% on average per year.
EPS 1Y (TTM)37.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-180.22%
Revenue 1Y (TTM)-95.87%
Revenue growth 3Y-64.23%
Revenue growth 5Y-48.41%
Sales Q2Q%-59.23%

3.2 Future

  • Based on estimates for the next years, KYNB will show a small growth in Earnings Per Share. The EPS will grow by 1.93% on average per year.
  • Based on estimates for the next years, KYNB will show a decrease in Revenue. The Revenue will decrease by -7.82% on average per year.
EPS Next Y-62.74%
EPS Next 2Y-20.46%
EPS Next 3Y1.93%
EPS Next 5YN/A
Revenue Next Year-7.58%
Revenue Next 2Y-11.67%
Revenue Next 3Y-7.82%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
KYNB Yearly Revenue VS EstimatesKYNB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M 250M
KYNB Yearly EPS VS EstimatesKYNB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

0

4. KYNB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for KYNB. In the last year negative earnings were reported.
  • Also next year KYNB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KYNB Price Earnings VS Forward Price EarningsKYNB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KYNB Per share dataKYNB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.46%
EPS Next 3Y1.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KYNB Dividend Analysis

5.1 Amount

  • No dividends for KYNB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KYNB Fundamentals: All Metrics, Ratios and Statistics

KYNTRA BIO INC

NASDAQ:KYNB (3/31/2026, 8:00:03 PM)

6.78

+0.32 (+4.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-16
Earnings (Next)05-11
Inst Owners28.22%
Inst Owner ChangeN/A
Ins Owners1.49%
Ins Owner Change-1.17%
Market Cap27.46M
Revenue(TTM)6.44M
Net Income(TTM)183.45M
Analysts80
Price Target43.86 (546.9%)
Short Float %2.84%
Short Ratio3.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.67%
Min EPS beat(2)8.9%
Max EPS beat(2)20.44%
EPS beat(4)4
Avg EPS beat(4)48.62%
Min EPS beat(4)8.9%
Max EPS beat(4)145.1%
EPS beat(8)8
Avg EPS beat(8)67.48%
EPS beat(12)9
Avg EPS beat(12)41.88%
EPS beat(16)12
Avg EPS beat(16)34.31%
Revenue beat(2)0
Avg Revenue beat(2)-23.89%
Min Revenue beat(2)-35.68%
Max Revenue beat(2)-12.1%
Revenue beat(4)1
Avg Revenue beat(4)-4.92%
Min Revenue beat(4)-49.76%
Max Revenue beat(4)77.86%
Revenue beat(8)4
Avg Revenue beat(8)2%
Revenue beat(12)7
Avg Revenue beat(12)2.3%
Revenue beat(16)9
Avg Revenue beat(16)6.81%
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)21.79%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-13.25%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.32%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.26
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.49
EYN/A
EPS(NY)-12.19
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS1.59
BVpS-7.42
TBVpS-7.42
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 153.4%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 2848.63%
GM 91.35%
FCFM N/A
ROA(3y)21.37%
ROA(5y)-4.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.18%
GM growth 5Y-0.78%
F-Score5
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.08%
Cap/Sales 0.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.39
Quick Ratio 3.26
Altman-Z -20.36
F-Score5
WACC12.83%
ROIC/WACCN/A
Cap/Depr(3y)13.44%
Cap/Depr(5y)121.93%
Cap/Sales(3y)2.29%
Cap/Sales(5y)9.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-180.22%
EPS Next Y-62.74%
EPS Next 2Y-20.46%
EPS Next 3Y1.93%
EPS Next 5YN/A
Revenue 1Y (TTM)-95.87%
Revenue growth 3Y-64.23%
Revenue growth 5Y-48.41%
Sales Q2Q%-59.23%
Revenue Next Year-7.58%
Revenue Next 2Y-11.67%
Revenue Next 3Y-7.82%
Revenue Next 5YN/A
EBIT growth 1Y65.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.31%
EBIT Next 3Y-7.26%
EBIT Next 5YN/A
FCF growth 1Y96.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y96.54%
OCF growth 3YN/A
OCF growth 5YN/A

KYNTRA BIO INC / KYNB Fundamental Analysis FAQ

What is the fundamental rating for KYNB stock?

ChartMill assigns a fundamental rating of 2 / 10 to KYNB.


What is the valuation status for KYNB stock?

ChartMill assigns a valuation rating of 0 / 10 to KYNTRA BIO INC (KYNB). This can be considered as Overvalued.


What is the profitability of KYNB stock?

KYNTRA BIO INC (KYNB) has a profitability rating of 3 / 10.


What is the earnings growth outlook for KYNTRA BIO INC?

The Earnings per Share (EPS) of KYNTRA BIO INC (KYNB) is expected to decline by -62.74% in the next year.